Table 2 Fibromyalgia Impact Questionnaire scores throughout the study period
From: Trazodone for the treatment of fibromyalgia: an open-label, 12-week study
baseline | week 6 | week 12 | P (anova) | ||
|---|---|---|---|---|---|
Total score (mean ± s.d.) | 77.5 ± 13.4 | 70.8 ± 15.8*** | 67.9 ± 17.9*** | < 0.0001 | |
ES | 0.5 | 0.72 | |||
Work (mean ± s.d.) | 8.15 ± 1.6 | 7.42 ± 2.0** | 7.43 ± 2.1** | = 0.0014 | |
ES | 0.46 | 0.45 | |||
Pain (mean ± s.d.) | 8.26 ± 1.7 | 7.78 ± 1.7* | 7.46 ± 1.9*** | = 0.0007 | |
ES | 0.28 | 0.47 | |||
Fatigue (mean ± s.d.) | 8.75 ± 1.4 | 8.09 ± 2.1* | 8.03 ± 2.1* | = 0.0140 | |
ES | 0.47 | 0.51 | |||
Morning tiredness (mean ± s.d.) | 8.86 ± 1.4 | 7.78 ± 2.4** | 7.72 ± 2.6** | = 0.0005 | |
ES | 0.77 | 0.81 | |||
Stiffness (mean ± s.d.) | 8.04 ± 2.0 | 7.12 ± 2.8** | 6.94 ± 2.8*** | = 0.0006 | |
ES | 0.46 | 0.55 | |||
Anxiety (mean ± s.d.) | 8.15 ± 1.9 | 7.44 ± 2.7* | 7.04 ± 2.7*** | = 0.0010 | |
ES | 0.37 | 0.58 | |||
Depression (mean ± s.d.) | 7.94 ± 2.5 | 6.98 ± 2.9 | 7.06 ± 3.0 | = 0.0027 | |
ES | 0.38 | 0.35 |